In vitro comparative activity of moxalactam, GR 20263, and N-formimidoyl thienamycin to other beta-lactam antibiotics and tobramycin against enterobacteriaceae and staphylococci.
The in vitro activities of moxalactam, GR 20263, and N-formimidoyl thienamycin were compared to those of cephalothin, cefazolin, cefamandole, cefoxitin, and tobramycin against 152 strains of Enterobacteriaceae and staphylococci. The results showed that moxalactam, GR 20263, and N-formimidoyl thienamycin each had significantly improved activity toward the gram-negative organisms tested compared to the other beta-lactams and tobramycin. N-formimidoyl thienamycin was particularly impressive with respect to its activity toward Staphylococcus aureus and S. epidermidis as compared to moxalactam, GR 20263 and the older beta-lactam drugs.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002442:Ceftazidime; D002511:Cephalosporins / Q000494:pharmacology; D002513:Cephamycins / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects*; D015378:Imipenem; D008826:Microbial Sensitivity Tests; D009070:Moxalactam; D013210:Staphylococcus / Q000187:drug effects*; D014031:Tobramycin / Q000494:pharmacology; D047090:beta-Lactams / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002513:Cephamycins; D047090:beta-Lactams; D015378:Imipenem; D002442:Ceftazidime; D009070:Moxalactam; D014031:Tobramycin